Pharvaris N.V. (NASDAQ:PHVS)
| Market Cap | 2.19B+37.6% |
| Revenue (ttm) | 0 |
| Net Income | -171.57M-0.6% |
| EPS | -2.70+12.6% |
| Shares Out | 69.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 621,705 |
| Open | 31.57 |
| Previous Close | 30.68 |
| Day's Range | 30.25 - 32.12 |
| 52-Week Range | 21.02 - 43.25 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 60.73(+93.35%) |
| Earnings Date | Nov 11, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About PHVS
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$PHVS stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in PHVS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PHVS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PHVS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New PHVS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PHVS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in PHVS
| ETF | Est. Holding Size |
|---|---|
| IBBiShares Biotechnology ETF | $7.74M |
| IEFAiShares Core MSCI EAFE ETF | $3.99M |
| SCZiShares MSCI EAFE Small-Cap ETF | $2.58M |
| EWNiShares MSCI Netherlands ETF | $1.48M |
| BBCVirtus Biotech Clinical Trials ETF | $316.92K |
| COROiShares International Country Rotation Active ETF | $269.46K |
Estimated from each fund’s disclosed top holdings × AUM
PHVS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from PHVS’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score